newsfilter
← Latest News
GlobeNewswire·

Larimar Therapeutics Reports Second Quarter 2025 Financial Results

Initial data from the 50 mg dose in the open label study and the adolescent PK run-in study planned for program update in September 2025Adolescent participants from the PK run-in study and patients with FA who have not